To Compare and Evaluate the Efficacy and Safety of Ganilever PFS(Prefilled Syringe) and Orgalutran®

Exclusion Criteria

• •If the sperm donor (spouse or non-spouse) is a severe male factor (Non obstructive azoospermia)
• •Patients who were diagnosed as PCOS (polycystic ovary syndrome) during screening
• •Patient with abnormal uterine bleeding during screening
• •Patients diagnosed with primary ovarian failure
• •Patients who has ovarian cysts that are not related to PCOS during screening
• •Patients with tubal hydrops
• •Patients with untreated non-reproductive endocrine disease
• •Patients with a deformity of the reproductive organs that can not be conceived, or fibroids of the uterus that can not be conceived (only for submucosal myoma)
• •Patients with less than 2 ovaries (0 or1)
• •Patients with ovarian, breast, uterus, hypothalamus, or pituitary malignancies
• •Patients with BMI \<18 or BMI\> 30
• •Patients with an LH concentration of less than 1.2mIU / mL during screening
• •Poor ovarian responder by bologna criteria
• •Patients with moderate or severe renal impairment (creatinine clearance \<60 mL / min) or liver function impairment (ALT or AST,\> 5 times normal)
• •Patients who experienced Grade 4 or higher OHSS (ovarian hyperstimulation syndrome) before
• •Patients who are contraindicated for pregnancy
• •Patients being pregnant or lactating
• •Patients with hypersensitivity to IP
• •Patients who have participated in other medication-related clinical trials since enrollment in this study, or have participated in other clinical trials within 3 months (90 days) before enrolling in this trial